{
    "clinical_study": {
        "@rank": "154732", 
        "arm_group": {
            "arm_group_label": "Group A", 
            "description": "Pre-adolescents (aged (\u226511 years to <12 years), adolescents (aged \u226512 to <19 years) and adults (aged \u226519 years) who received Boostrix as a part of routine practice at a private clinic or hospital in Korea."
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to collect safety information from pre-adolescents, adolescents\n      and adults after Boostrix vaccination is administered according to the approved prescribing\n      information in Korea."
        }, 
        "brief_title": "Post-marketing Surveillance to Assess the Safety of Boostrix Vaccine Given According to Prescribing Information in Korea", 
        "completion_date": {
            "#text": "January 2016", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Tetanus", 
            "Acellular Pertussis", 
            "Diphtheria"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Diphtheria", 
                "Whooping Cough", 
                "Tetanus", 
                "Tetany"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Written or signed informed consent obtained from the subject/ subject's\n             parent(s)/Legally Acceptable Representative(s) of the child. Korean male or female\n             subjects who were recently vaccinated or eligible to receive Boostrix according to\n             the locally approved Prescribing Information.\n\n        Exclusion Criteria:\n\n          -  Those who are not eligible for vaccination according to the local Prescribing\n             Information.\n\n          -  Child in care."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "64 Years", 
            "minimum_age": "11 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Pre-adolescents, adolescents and adults who receive Boostrix as a part of routine practice\n        at a private clinic or hospital."
            }
        }, 
        "enrollment": {
            "#text": "600", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 22, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01929291", 
            "org_study_id": "115374"
        }, 
        "intervention": [
            {
                "arm_group_label": "Group A", 
                "description": "Single intramuscular injection", 
                "intervention_name": "Boostrix", 
                "intervention_type": "Biological", 
                "other_name": "dTPa vaccine"
            }, 
            {
                "arm_group_label": "Group A", 
                "description": "Safety monitoring: recording of adverse events using diary cards and recording of serious adverse events using the latest version of Korea's Post-Marketing Surveillance Serious Adverse Event Reporting Form", 
                "intervention_name": "Safety data collection", 
                "intervention_type": "Other"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "Korea", 
            "Post-marketing surveillance", 
            "Boostrix", 
            "Prescribing information", 
            "Safety"
        ], 
        "lastchanged_date": "December 5, 2013", 
        "location": {
            "contact": {
                "email": "GSKClinicalSupportHD@gsk.com", 
                "last_name": "US GSK Clinical Trials Call Center", 
                "phone": "877-379-3718"
            }, 
            "contact_backup": {
                "email": "GSKClinicalSupportHD@gsk.com", 
                "last_name": "EU GSK Clinical Trials Call Center", 
                "phone": "+44 (0) 20 8990 4466"
            }, 
            "facility": {
                "address": {
                    "city": "Suwon-si", 
                    "country": "Korea, Republic of", 
                    "zip": "443-380"
                }, 
                "name": "GSK Investigational Site"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_groups": "1", 
        "official_title": "Assessment of Safety of GlaxoSmithKline (GSK) Biologicals' Combined Reduced Antigen Content Diphtheria-tetanus Toxoids and Acellular Pertussis Vaccine (dTPa), Boostrix When Administered According to the Approved Prescribing Information in Korea", 
        "overall_contact": {
            "email": "GSKClinicalSupportHD@gsk.com", 
            "last_name": "US GSK Clinical Call Center", 
            "phone": "877-379-3718"
        }, 
        "overall_official": {
            "affiliation": "GlaxoSmithKline", 
            "last_name": "GSK Clinical Trials", 
            "role": "Study Director"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Korea: Korea Food & Drug Administration"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "January 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Occurrence of adverse events", 
                "safety_issue": "No", 
                "time_frame": "During the 30-day (Day 0 - Day 29) follow-up period after vaccination"
            }, 
            {
                "measure": "Occurrence of serious adverse events", 
                "safety_issue": "No", 
                "time_frame": "Starting at Visit 1 in the post-marketing surveillance up to 30 days (Day 0 to Day 29) after the vaccine is administered"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01929291"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "GlaxoSmithKline", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "GlaxoSmithKline", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "September 2013", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "October 2013"
    }
}